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Abstract: Beyond acute clinical conditions, the role
of enteroviruses (EVs) in chronic human diseases
has been described. Although they are considered as
highly cytolytic viruses, EVs can persist in various
tissues. The persistence is believed to play a major
role in the pathogenesis of EV related chronic dis-
eases such as type 1 diabetes (T1D). T1D is charac-
terized by an autoimmune destruction of pancreatic
beta cells, and results from interplay between a
genetic predisposition, the immune system, and
environmental factors. EVs and especially group B
coxsackieviruses (CVB) have been the most incrimi-
nated as exogenous agents involved in the develop-
ment of T1D. Enteroviral persistence is the result of
a virus-host coevolution combining a cell resistance
to lysis through mutations or down-regulation of
viral receptor, and a decrease of the viral replication
by genomic modifications or the production of a sta-
ble double-stranded RNA form. CVB can persist in
pancreatic cells and therefore could trigger, in genet-
ically predisposed individuals, the autoimmune
destruction of beta cells mainly through an activa-
tion of inflammation. The persistence of the virus in
other tissues such as intestine, blood cells, and thy-
mus has been described, and could also contribute to
some extent to the enteroviral pathogenesis of T1D.
The molecular and cellular mechanisms of CVB per-
sistence and the link with the development of T1D
should be investigated further. [Discovery Medicine
18(100):n-n, November 2014]
Introduction
Human enteroviruses (HEVs) include many major
human pathogens such as poliovirus, rhinovirus,
enterovirus 71, coxsackievirus, and echovirus. These
small non-enveloped RNA viruses belong to the
Picornaviridae family, and the genus Enterovirus cur-
rently encompasses 7 species involved in human dis-
eases (Human enterovirus A-D and Human rhinovirus
A-C) (Knowles et al., 2012; Tapparel et al., 2013).
Non-polio enteroviruses are ubiquitous pathogens and
can infect a wide range of tissues (Harvala et al., 2002).
They can be involved in many severe acute clinical fea-
tures such as meningitis, encephalitis, myocarditis, pan-
creatitis, hepatitis, or fulminant sepsis in newborns
(Romero, 2008; Tapparel et al., 2013).
Enteroviruses (EVs), especially the group B
Coxackieviruses (CVB1-6), have also been associated
with the development of chronic diseases like type 1
diabetes (T1D). T1D is characterized by a defect of
insulin production as a result of an autoimmune
destruction/dysfunction of pancreatic β cells in geneti-
cally predisposed individuals with an impaired immune
regulation (Roep and Tree, 2014); but the role of exoge-
nous factors in the initiation and progression of this dis-
order seems obvious, since only a small proportion of
genetically susceptible individuals progress to clinical
disease (Knip and Simell, 2012). Enteroviruses and
especially CVB have been the most incriminated as
environmental factors, and a relationship between these
viruses and the development of T1D has been reported
(Hober and Alidjinou, 2013; Hober and Sauter, 2010;
Morgan and Richardson, 2014).
Although EVs are cytolytic viruses, they can establish
persistent infections in vitro as well as in vivo (Pinkert
et al., 2011), and viral persistence has been suggested as
a major mechanism in the enteroviral pathogenesis of
T1D (Jaïdane and Hober, 2008; Jaïdane et al., 2010).
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nEpidemiological studies have found, in T1D patients, a
more frequent detection of enteroviral (EV) compo-
nents in blood, in the intestine, and in pancreas (Yeung
et al., 2011), most often beyond the stage of acute infec-
tion.
The persistence of EVs has already been associated in
humans to other syndromes, including post-polio syn-
drome (Julien et al., 1999; Leparc-Goffart et al., 1996)
and chronic fatigue syndrome (Chia et al., 2010).
Furthermore, CVB persistence was shown to contribute
significantly to the occurrence of chronic myocarditis
and dilated cardiomyopathy through direct effects of
viral replication as well as induction of inflammation in
the heart (Chapman and Kim, 2008).
EVs are transmitted mainly by fecal-oral route and their
primary replication occurs in the intestine mucosa.
From the gut, a systemic infection can lead to dissemi-
nation of the virus to other target organs such as pan-
creas. Although the presence or the persistence of the
virus in the pancreas is believed to be a major compo-
nent of the enteroviral pathogenesis of T1D, the virus
can also persist in other sites such as intestine or blood
cells that could act as reservoir and contribute to the cir-
culation of the virus and the maintenance of pancreatic
cells infection.
In addition, CVB can infect the thymus, whose most
important role is the induction of central tolerance, i.e.,
the ability of T cells to discriminate ‘self’ from ‘non-
self.’ A persistent CVB infection of thymic cells could
lead to the disturbance of immune tolerance and con-
tribute to the autoimmune process in T1D, by loss of
central self-tolerance to insulin-secreting pancreatic β
cells (Jaïdane et al., 2012a).
After a brief presentation of the currently known molec-
ular mechanisms of EV persistence, the cumulative evi-
dence in vitro and in vivo regarding EV persistence
(with a focus on CVB) will be described in pancreatic
cells and also in the other potential sites, and the link
between the persistence and the pathological process
leading to the development of T1D will be analyzed.
Factors Involved in the Persistence of EVs in Tissues
EVs are considered as cytolytic viruses; however, they
can establish persistent infections in vitro as well as in
vivo (Frisk, 2001; Pinkert et al., 2011). This suggests
the role of a regulatory mechanism of viral replication
under certain circumstances. Two major groups of per-
sistent viral infections have been described: steady-
state infections and carrier-state infections. The first
group is characterized by infection of all cells (without
lytic replication cycle), whereas in carrier-state culture
systems, only a small proportion of cells are involved
(with productive virus replication) (Frisk, 2001; Pinkert
et al., 2011). EVs and especially CVB were shown to
establish carrier-state persistent infections in vitro
(Heim et al., 1992; 1995; Pinkert et al., 2011).
Most of the knowledge on viral persistence comes from
in vitro systems, with some from in vivo models.
Actually persistent infection by cytolytic viruses such
as EVs is thought to result from a virus-host coevolu-
tion which combines a resistance developed by the cell,
and an adaptation of the virulence of the viral strain
(Pinkert et al., 2011). In this section, viral and cellular
factors involved in the persistence of EVs are reviewed.
Viral factors are undoubtedly the most studied parame-
ters during EV persistence. Since RNA-dependent
RNA polymerases lack proofreading, the main mecha-
nism reported is the selection of virus mutants that are
less cytopathic for cells or that result in low-level viral
replication. Some mutations were reported to affect the
binding properties of the virus. A combination of muta-
tions in the VP1 and VP2 capsid genes of poliovirus
(PV) was shown to affect the cell binding and the recep-
tor-mediated conformational changes necessary for
viral penetration and uncoating. This modification has
been suggested as the mechanism by which PV is able
to establish persistent infections in HEp-2 cell cultures
(Duncan and Colbère-Garapin, 1999; Duncan et al.,
1998; Pelletier et al., 1998). Some amino-acid substitu-
tions described in CVB3 strain emerging during viral
persistence were associated with a weak interaction
with the coxsackie and adenovirus receptor (CAR) but
strong binding to the decay accelerating factor (DAF),
as compared to the parental virus (Schmidtke et al.,
2000).
Other genomic alterations have been reported in the EV
highly conserved 5′NTR region. This region was shown
to harbor the genomic determinants of EV replication
(Bedard and Semler, 2004). Chapman and colleagues
have demonstrated that in vivo CVB3 persistent infec-
tion of mouse or human heart, as well as in vitro infec-
tion of cardiomyocytes, was associated with a deletion
in the 5′ end of the RNA. These ‘terminally deleted’
viruses have a lower replication rate and can persist in
host cells over a prolonged period (Chapman et al.,
2008; Kim et al., 2005; 2008). Recently, this deletion
was also reported in a murine model during CVB per-
sistence in the pancreas (Tracy et al., 2014).
The genomic modifications during EV persistence
could explain at least partially the low detection rate of
EV RNA by RT-PCR in samples from patients with EV
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associated chronic diseases. However, an alternative
viral persistence mechanism is possible especially in
vivo. Indeed, it has been described that EV persistence
in muscle and probably in other nondividing cells was
not associated with the selection of mutant virus, but
with the presence of a stable and atypical double-
stranded RNA genomic form. Myofibers can harbor this
RNA form for extended times without a production of
detectable levels of infectious virus (Cunningham et al.,
1990; Klingel et al., 1992; Tam and Messner, 1999).
Few authors have focused on the cellular factors
involved in EV persistence. Feuer et al. (2002; 2004)
reported that the cell cycle status affects CVB3 replica-
tion and suggested that the persistence of CVB3 in vivo
may rely on infection of quiescent cells in which viral
replication is lowered or suppressed. Cellular activation
may also play a role in the outcome of CVB infection
(Feuer and Whitton, 2008). The role of receptor muta-
tions or reduction of receptor expression has been
reported for EV persistence. Specific mutations in the
Figure 1. Possible mechanisms involved in the persistence of coxsackievirus B. A cytolytic virus such as coxackievirus
B (CVB) can establish under certain circumstances a persistent infection in susceptible cells. Changes in cell and virus
characteristics leading to a decreased or suppressed viral replication can be observed when the infection is persistent.
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domain 1 of poliovirus receptor (PVR) were associated
with an increase of cell resistance to lysis (Pavio et al.,
2000), and a decrease of PV-induced apoptosis
(Gosselin et al., 2003). A down-regulation of CAR has
been reported during CVB3 persistence (Pinkert et al.,
2011), and a decrease of CAR expression was known to
be associated with a decrease of CVB infection and cell
lysis (Fechner et al., 2007; Werk et al., 2005). A heart-
specific deletion of CAR in mice resulted in a resist-
ance to CVB infection (Shi et al., 2009).
In summary, EV persistence depends strictly on the
interactions within the virus-cell system. It probably
combines many of the mechanisms described above,
and others unknown. A better understanding of this
phenomenon will provide a molecular basis to the
pathogenesis of enterovirus-related chronic diseases
like T1D.
EV Persistence in Pancreatic Cells and Relationship
with T1D 
The understanding of the pathogenesis of T1D requires
undoubtedly focusing on pancreas. The pancreatic tro-
pism of EVs both in animals and humans is well
known. In humans, the evidence of enteroviral infec-
tion within pancreatic cells at the onset or during the
progression of the disease has been difficult to obtain
since this requires a biopsy that is invasive and often
risky. Therefore, most of data available come from
necropsies (Dotta et al., 2007; Richardson et al., 2009;
Willcox et al., 2011; Ylipaasto et al., 2004). Pancreatic
islets and especially β-cells, but not exocrine cells,
Figure 2. Persistence of coxsackievirus B and relationship with type 1 diabetes. Coxsackievirus B (CVB) can persist in
pancreas and trigger autoimmunity in predisposed individuals through the activation of inflammation, resulting in the
destruction of β-cells by preexisting autoreactive T cells. The inhibition of trans-differentiation through persistent infec-
tion of ductal cells can contribute to the β-cell deficiency. Other tissues, such as intestine and blood, in which CVB can
persist, may act as virus reservoir for pancreas infection or reinfection. The persistence of CVB in thymus can contribute
to the onset of autoimmunity through the disturbance of self tolerance. 
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were found to be susceptible to enteroviral infection
(Dotta et al., 2007; Richardson et al., 2009; 2013).
Interestingly, the specific receptor of cosackieviruses,
the CAR molecule, is expressed in the pancreas mainly
by these β-cells (Oikarinen et al., 2008a; Spagnuolo et
al., 2013).
CVB can effectively replicate in pancreatic cells and
cause massive cell lysis (Anagandula et al., 2014;
Elshebani et al., 2007; Hodik et al., 2013). In vivo, this
extensive cell destruction upon CVB infection could
lead to what is known as “fulminant diabetes”
(Kobayashi et al., 2011; Tanaka et al., 2013), a particu-
lar and rare clinical feature especially described in
Japanese patients (out of the scope of this review).
Things are different in CVB associated autoimmune
T1D since a clinical disease occurs often many years
after the appearance of islet specific autoantibodies
which have been reported to be a result of enteroviral
infection (Laitinen et al., 2014; Oikarinen et al., 2011).
Such important damage is not observed in pancreatic
cells of patients in which the virus components have
been detected. The most likely scenario would be a per-
sistent infection with probably a low grade viral repli-
cation.
In fact the outcome of CVB infection within pancreat-
ic cells seems to depend on the serotype and even the
strain of the virus (Elshebani et al., 2007; Frisk and
Diderholm, 2000; Frisk et al., 2001; Hindersson et al.,
2004; Roivainen et al., 2002; Tracy et al., 2000). In
addition, the route of transmission was reported to
impact the effect of CVB on pancreatic cells. Indeed, a
study has compared intraperitoneal injection and oral
administration in mice, and concluded that though both
routes lead to systemic and pancreas infection, the oral
administration that is the natural transmission route in
humans, protects pancreas from damage (Bopegamage
et al., 2005). This finding suggests that the viral titer
reaching the pancreas after oral administration is lower,
resulting in a non-highly cytopathic phenomenon.
It is well accepted that the selective destruction of beta
cells in T1D patients is an autoimmune process (Roep
and Tree, 2014). The main hypothesis addressing the
relationship between CVB persistence and T1D is that
non-cytopathic CVB infection triggers autoimmunity
against beta cells through activation of inflammation.
Actually, pathological studies on pancreases from died
T1D patients (Richardson et al., 2014) show a quasi-
absence of beta cells and the presence of an inflamma-
tory cell infiltrate (insulitis) composed mainly of CD8
cytotoxic T cells and at lesser extent CD4 T cells and
macrophages, and sometimes NK cells were reported
(Dotta et al., 2007; Willcox et al., 2009).
Persistent CVB infection is thought to induce an
inflammatory response (and especially IFNα produc-
tion) in pancreatic endocrine cells. Yet, this response
might depend on a genetic background since some
polymorphisms of IFIH1 gene have been epidemiolog-
ically associated with an increased risk of T1D
(Nejentsev et al., 2009; Smyth et al., 2006). This gene
encodes for MDA5 protein which is a cytoplasmic
innate immune sensor for CVB (Kato et al., 2006). The
local inflammation could lead to a beta cell antigen
presentation that is enhanced by the hyperexpression of
class I major histocompatibility complex (MHC) by
endocrine cells (Richardson et al., 2014). The result of
this antigen presentation is a destruction of beta cells
by CD8 cytotoxic T cells that interestingly were found
to be antigen-specific (Coppieters and von Herrath,
2009). These T cells probably preexist in predisposed
individuals and are recruited to islets, guided by anti-
gen presentation and driven by chemokines (Roep et
al., 2010; Sarkar et al., 2012).
In contrast to the non-obese diabetic (NOD) model, the
insulitis seems to be moderate in humans, and only a
limited number of infiltrating cells are observed
(Carrero et al., 2013; Willcox et al., 2009). In vitro
studies confirmed that pancreatic islets can support per-
sistent CVB infection which results in a production of
IFNα (Chehadeh et al., 2000a), and a disturbance in the
function of beta cells (Yin et al., 2002a).
Other mechanisms involving persistent CVB infection
in T1D could include molecular mimicry and an inhibi-
tion of the trans-differentiation of pancreatic ductal
cells. The hypothesis of molecular mimicry is support-
ed by the homology between a conserved sequence of
the enteroviral 2C protein and glutamate decarboxylase
(GAD), an autoantigen frequently detected in T1D
patients (Hou et al., 1994; Kaufman et al., 1992). This
possibility has not been investigated further, since CVB
infections have been associated with T1D only in some
patients, and this autoantigen was also reported to share
some homologies with other viral peptides (Hiemstra et
al., 2001; Honeyman et al., 2010).
The trans-differentiation of pancreatic ductal cells is
thought to be a renewal process of beta cells following
a loss of these cells in a context of T1D, for example.
An inhibition of this phenomenon could contribute to a
rapid development of T1D (Lysy et al., 2013; Sane et
al., 2013). Interestingly, our team has established a per-
sistent CVB infection in a pancreatic ductal cell line
(Panc-1 cells), and found that the persistent infection
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reduced the expression of Pdx-1, a transcriptional factor
required for the differentiation of ductal cells (Sane et
al., 2013).
EV Persistence in Other Tissues and Relationship
with T1D
EV persistence in the intestine
After transmission most of time by oral route, CVB can
replicate effectively in the gastrointestinal tract and
especially in the intestine, and thereafter can spread
from this site to the pancreas or other target organs.
However, intestine is not just a crossing for the virus
and there is some evidence that EV can establish a per-
sistent infection in the intestine. Oikarinen et al.
(2008b; 2012) have detected the presence of EV in the
mucosa of small intestine of T1D patients but not in
controls. Interestingly, patients remained EV positive 12
months after, and evidence of intense viral replication
was not observed, suggesting a persistence of the virus
in the gut of these patients (Oikarinen et al., 2012). In
addition, enteroviral infection was associated to a
chronic inflammation in the intestine (Oikarinen et al.,
2012). This finding is compatible with previous reports
which found an enhanced immune activation in the
small intestine of T1D patients (Westerholm-Ormio et
al., 2003). This environment could constitute a reservoir
from which the virus spreads to the pancreas and trig-
gers autoimmunity, since intestine is highly vascular-
ized. Nevertheless, the hypothesis of the role of gut in
the persistence of enteroviruses in patients with T1D
should be investigated further, since data reported by
Oikarinen et al. were not confirmed by those of another
team (Mercalli et al., 2012). In vitro, the persistence of
CVB in human intestinal cell line (Caco-2 cells) has
been demonstrated (Harrath et al., 2004; Riabi et al.,
2012). However, cells involved in the replication and
the persistence of CVB in vivo in the intestine have not
been precisely identified. In infected mice, the virus was
reported to predominate in the lymphoid cells of the gut
mucosa (Harrath et al., 2004).
EV persistence in blood cells
The blood is the main vehicle that spreads the virus in
the whole body. The majority of epidemiological stud-
ies that investigated the relationship between EVs and
T1D have focused on blood because it can be easily
sampled by venipuncture. Thus, a large number of
reports have found a more frequent detection of
enteroviral RNA in the blood of T1D patients as com-
pared to healthy individuals. EV RNA has been detect-
ed in the blood long before onset of clinical T1D and up
to 6 months before the appearance of diabetes-associat-
ed autoantibodies (Oikarinen et al., 2011), and more-
over the virus has been found both in recent and long-
term diabetic patients (Yeung et al., 2011).
Most of these investigations were performed using
whole blood or serum, and few authors focused on the
blood cells that could harbor the virus (Chehadeh et al.,
2000b; Salvatoni et al., 2013; Schulte et al., 2010;
Toniolo et al., 2010; Yin et al., 2002b). EV RNA has
been detected in peripheral blood mononuclear cells
(PBMCs) of T1D at a relatively higher rate than in plas-
ma or serum (Schulte et al., 2010; Yin et al., 2002b). In
addition, EV RNA was still detected in blood beyond
the stage of acute infection, after the detection of EV
RNA in throat and stool samples was negative (Schulte
et al., 2010). These data suggest that EVs can be detect-
ed in PBMCs during and after the “viremic” stage.
Experiments performed in our laboratory have shown
that among PBMCs of T1D patients, EV RNA was har-
bored mainly by monocytes, which also displayed an
increase in susceptibility to enteroviral infection in vitro
(Alidjinou et al., submitted). Although monocytes are
poorly permissive to enteroviral infection in vitro, they
can be efficiently infected under some circumstances,
especially the presence of enhancing antibodies
(Chehadeh et al., 2005; Hober et al., 2001). Moreover,
our team has shown that CVB mixed with enhancing
IgG can establish a persistent infection in a monocytic
cell line (Goffard et al., 2013).
It can therefore be hypothesized that PBMCs and espe-
cially monocytes could constitute a reservoir contribut-
ing to the enteroviral infection or reinfection of target
organs such as pancreas. Whether macrophages can
play a role in the persistence of CVB deserves further
investigations.
EV persistence in the thymus
The thymus, a primary lymphoid organ, is a major com-
ponent of immune system and the site of initiation of
self-tolerance. The self-antigens are expressed within
the thymus, and self-tolerance is established during T-
cell ontogeny by elimination of autoreactive T lympho-
cytes (negative selection). In addition, self-antigen-spe-
cific natural regulatory T cells (nTregs) are generated to
inactivate periphery self-reactive T cells that have
escaped negative selection (Klein et al., 2009). A distur-
bance of thymus function can initiate an autoim mune
process, and since T1D is an autoimmune disease, it
makes sense to explore the involvement of the thymus
in its pathogenesis.
The thymus is a target for EV infection as supported by
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reports in humans (Cavalcante et al., 2010) and in ani-
mal models (Jaïdane et al., 2006). After inoculation by
oral route in mice, CVB can infect the thymus and viral
RNA is still detected until 70 days post-inoculation
(Jaïdane et al., 2006).
In vitro, human epithelial thymic cells can be infected
by various strains of CVB4. The virus can replicate and
persist in these cells, and induces the production of
interleukin (IL)-6, leucocyte migration inhibition factor
(LIF), and granulocyte-macrophage colony-stimulating
factor (GM-CSF) (Brilot et al., 2002). CVB4 can infect
immature thymocytes in human fetal thymus, which
results in an increased expression of class I MHC mol-
ecules and a severe depletion of thymocytes (Brilot et
al., 2004).
The CVB infection of murine thymic cells in vitro was
reported to disturb the T-cell maturation and differenti-
ation processes (Brilot et al., 2008; Jaïdane et al.,
2012a).
Recently our team established a persistent CVB4 infec-
tion in murine thymic epithelial cell line. The infection
led to a decrease in the production of type 2 insulin-like
growth factor (Igf2), the dominant polypeptide of the
insulin family, which has a tolerogenic effect towards
insulin (Jaïdane et al., 2012b). A defect of Igf2 expres-
sion in the thymus was suggested to play a role in the
development of autoimmune diabetes in a BBDP rat
model (Kecha-Kamoun et al., 2001).
These data suggest that it cannot be excluded that a per-
sistent CVB infection of the thymus could disturb self-
tolerance at the central level, and could then play a role
in the pathogenesis of T1D.
Conclusion
Enteroviruses can be involved in acute and lytic infec-
tions, but they can also persist in tissues through an
adaptation of characteristics of both virus and host cell.
This persistence is thought to be the main mechanism in
the pathogenesis of chronic enterovirus-related dis-
eases. EVs and especially CVB can persist in pancreas,
leading to, in predisposed individuals, a progressive
and moderate inflammatory response that can activate
the beta-cell autoimmune destruction process by preex-
isting cytotoxic T cells. In addition, a persistence of
CVB can also occur in other sites such as intestine or
blood cells that could serve as a reservoir for infection
or reinfection of pancreas, and in thymus resulting in a
defect of central self-tolerance that could lead to
autoimmune diseases such as T1D.
Further in vivo and in vitro studies are still needed for a
better understanding of the molecular mechanisms of
enteroviral persistence in these tissues, and its contribu-
tion to the pathogenesis of T1D.
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